Skye Bioscience Inc (QB) (SKYE) Quote

Longs do your DD Before Investing . Avatar Dhillon to be Sentenced on 5/23/24 For Securities Fraud ; Multiple Counts .
63 to 78 Months in Federal Penitentiary Pending. He Turn states Evidence for a Deal against his former Business associates .
Skye continues with Family members in control . LONG History of Name Rebranding for many Years here.
ALL FACTS . DO YOUR RESEARCH !

SKYE moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

Definitely $SKYE crime family & today the market is finally realizing that reality!

Is this real or a crime family moving one companies bankrupt assets to another family company to do it again?

SEC Fraud is no trivial matter as it relates to investing ... nice that Avtar Dhillon Resigned from Emerald Therapeutics [ now Skye Bioscience ] as he knew once convicted by the SEC he would be Barred from the Market as well as Fined over 10 Million Dollars.
like a good Rat he turned on fellow thieves and Testified on behalf of the SEC to get cut ''a Deal '' ..... POS .

News: Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa

https://ir.skyebioscience.com/news-events/press-releases/detail/183/skye-bioscience-and-tautomer-bioscience-enter-exclusive

Silk Purse Stock...

'' Could '' be ....

SKYED: Up 15% in the Post-Mkt., after its Frid. big RS --- even though still (ostensibly) on the OTC?? (Or, did it in fact jump to the NASDAQ, but not yet displayed as being there?? WHATEVER!!)

VWAP pre-split is $0.0159 on 2.47m volume (Sept07-2023). $SKYED post split equal value to yesterday's trading would be $3.98 per share. Slightly undervalue today, could be an opportunity to get cheap and discounted shares.

SKYE: one for 250 reverse split: (pps closed at .0175)

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

Reverse Stock Split to Be Effective on September 8th
Press Release | 09/07/2023
San Diego, California--(Newsfile Corp. - September 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary medicines that modulate the endocannabinoid system to treat diseases with inflammatory, fibrotic, and metabolic processes, announced today that the previously announced 1-for-250 reverse stock split of its issued and outstanding common stock will become effective on Friday, September 8th. Skye's common stock is expected to begin trading on a split-adjusted basis when the market opens on Friday, September 8th. Skye will continue to trade on the OTCQB® Market under the symbol SKYE, although the letter "D" will be temporarily appended to the ticker symbol for twenty (20) trading days following the reverse split.

As a result of the reverse stock split, each 250 pre-split shares of common stock outstanding will automatically be combined into one issued and outstanding share of common stock. No fractional shares of common stock will be issued as a result of the reverse stock split. Each fractional share will be rounded up to one whole share. The new CUSIP for the common stock following the reverse stock split will be 83086J200.

Following the reverse stock split, the total number of authorized shares of common stock will be 20,000,000 and approximately 12,312,551 shares of common stock will be issued and outstanding. Each stockholder's percentage ownership interest in Skye and proportional voting power will remain virtually unchanged except for minor changes and adjustments that will result from rounding fractional shares into whole shares. The rights and privileges of the holders of shares of common stock will be substantially unaffected by the reverse stock split. Under Nevada law, because the reverse stock split was approved by the Board of Directors of Skye in accordance with NRS Section 78.207, no stockholder approval is required.

Stockholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse stock split.

About Skye Bioscience

Skye is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor, to treat diseases with inflammatory, fibrotic, and metabolic processes. Backed by leading biotechnology venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first- and only-in-class therapeutics with significant clinical and commercial differentiation. SBI-100 Ophthalmic Emulsion is a CB1 agonist that is a potential treatment for glaucoma and is expected to start a Phase 2 clinical trial in Q4 2023. Nimacimab, a negative allosteric modulating antibody, inhibits peripheral CB1 with unprecedented safety and tolerability. A Phase 2 basket study for chronic kidney disease is expected to start in 2024. Skye is evaluating potential development paths for nimacimab related to obesity/weight loss. For more information, please visit: https://www.skyebioscience.com.

CONTACT Investor Relations Email: ir @logman

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "expects," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/179893

Picked up a little at .011 since such a massive sell off and half the price of the new warrants

1:250 RS with possible uplist per 8/21/23 news
https://www.otcmarkets.com/stock/SKYE/news?id=411321

News: Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion

https://www.newsfilecorp.com/release/169568

Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist

https://www.newsfilecorp.com/release/166391

Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion

https://www.newsfilecorp.com/release/166109

NEWS: Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist

https://www.newsfilecorp.com/release/163940

News: Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion

Enrollment started for multiple ascending dose arm of Phase 1 study

https://www.newsfilecorp.com/release/161189

News: Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal

https://www.newsfilecorp.com/release/160992

Don't live for the approval of others. Only person who can approve what you do is YOU.

NEWS:
Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion
https://www.newsfilecorp.com/release/158513

NEWS: Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

https://www.newsfilecorp.com/release/157499

San Diego, California--(Newsfile Corp. - March 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, has completed dosing of the third cohort of eight healthy participants in its Phase 1 clinical trial of its lead product candidate, SBI-100 Ophthalmic Emulsion ("OE"), a cannabinoid receptor type 1 ("CB1R") agonist administered topically onto the eye. The study's safety review committee ("SRC") provided a positive recommendation following a pre-specified review of the data from the second cohort of participants. The SRC also recommended the trial advance into the multiple ascending dose ("MAD") arm of the study. Skye has submitted to the human ethics review committee ("HREC") for approval to initiate the MAD arm.

The objective of this Phase 1, randomized, double-masked, placebo-controlled study is to evaluate the safety, tolerability and pharmacokinetics of SBI-100 OE. Changes in intraocular pressure will also be evaluated. Approximately 48 subjects are divided into three single ascending dose ("SAD") and then three subsequent MAD cohorts, with six participants receiving drug and two participants receiving placebo in each cohort. In the third and final SAD cohort, participants administered drug received a single topical dose of SBI-100 OE at a concentration of 2.0%, compared to concentrations of 0.5% and 1.0% in the first and second SAD cohorts.

Skye's SBI-100 OE possesses a novel molecular structure and nanoemulsion formulation that were designed to enable effective topical delivery and better penetration of a CB1R agonist into ocular tissue. In preclinical studies involving three different species, the drug resulted in enhanced therapeutic efficacy and duration of response in lowering IOP, comparing favorably to the standard of care for treating glaucoma.

NEWS: Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study

https://www.newsfilecorp.com/release/155905

News: Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors

https://www.newsfilecorp.com/release/155012

News: Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment

https://www.newsfilecorp.com/release/154878

News: Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

https://www.newsfilecorp.com/release/154551

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion

https://www.newsfilecorp.com/release/153334

News: Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort

https://www.newsfilecorp.com/release/153016

Wendy Wins

https://www.otcmarkets.com/filing/html?id=16340712&guid=cA2-kqMqjGyRdth

Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion

https://ir.skyebioscience.com/news-events/press-releases/detail/152/skye-bioscience-obtains-central-irb-approval-for-phase-2

News: Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.

https://finance.yahoo.com/news/pii-congratulates-skye-bioscience-first-130000450.html

Need out: Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE

https://www.newsfilecorp.com/release/148778

#DDAmanda / #8KSpy alert....... 8K Filed........

Z

The Company intends to initiate a Phase 2 study in participants with primary open angle glaucoma and ocular hypertension in the United States in the first half of 2023

Skye announced that it had submitted an Investigational New Drug application for SBI-100 OE to the U.S. Food and Drug Administration on November 15, 2022

Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion

https://seekingalpha.com/pr/19058863-skye-bioscience-doses-first-cohort-of-participants-in-phase-1-clinical-trial-of-sbiminus-100

Chris Twitty connections : ZyVersa Therapeutics to go public through deal with SPAC Larkspur Health Acquisition,

https://seekingalpha.com/search?list=all&q=zvsa&tab=headlines

https://s28.q4cdn.com/456742261/files/doc_news/2022/2022-09-27_ZyVersa_Therapeutics_and_Larkspur_Health_46.pdf

Larkspur Health Board Member

https://lsprhealth.com/team/person-details/default.aspx?ItemId=2a53eaee-0907-48c2-8080-91d1b8f70c8a

Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer

https://seekingalpha.com/pr/19053259-skye-bioscience-appoints-chris-twitty-phd-chief-scientific-officer

Yeah , sure but that being said it doesn't figure that you would not research the management of this Team and family member Avtar Dillion who just plead guilty to the SEC x 3 counts .
especially with your impressive Resume' .....

LMAO!!!!! What?

You got something to say to someone why don't you say something meaningful don't breathe?

Out here I'm trying to make some risk liquidity and some investment and avoid dilution should that be done as any part of investing son?

FWIW: SBI-100's pre-clinical trial data showed stronger and longer-lasting reduction in IOP compared to Xalatan/Latanoprost, already giving it the edge in terms of efficacy. If it's found to also offer neuroprotection that would make it clearly superior to its competitors. (See https://www.biospace.com/article/releases/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/)

I can't answer the market share / reinvention questions; they're above my pay grade. GLTA!

WTF? ......I only made it up to ILLliterate .

There are currently no less than 5 prescription medications available for IOP disorder , the most commonly prescribed would be Xalatan . if Skye got SBI-100 all the way through FDA approval , Why would this product be superior ?
and ....thus prescribed more so than the widely known Xalatan ?
what kind of market share $$$ are we talking to re-invent the wheel ?
TIA.....

SMH. Wow

That I in paid for it to gain with the company and value to my position how does it not make sense son what's the demand here what are you trying to alliterate?

NEWS: Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference

https://www.newsfilecorp.com/release/145231

This post makes no sense